Cataract

Ophthalmology·MeSH: Cataract

Prevalence

1359.5 / 100K

13 drugs in development·9 companies·7 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
bromfenac	Aptinyx Inc. (APTX)
bromfenac	Amneal Pharmaceuticals, Inc. (AMRX)
dextenza	OCULAR THERAPEUTIX, INC (OCUL)
ilevro	HARROW, INC. (IMMY)

Phase 3(3)

Drug	Company
bimatoprost drug pad-iol system	SpyGlass Pharma Inc. (SGP)
bimatoprost implant system	SpyGlass Pharma Inc. (SGP)
control	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(3)

Drug	Company
0.4% zoc2017217	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
0.4% zoc2017217	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
0.4% ZOC2017217	Crinetics Pharmaceuticals, Inc. (CRNX)

Preclinical(1)

Drug	Company
lanosterol	KUBOTA PHARMACEUTICAL HOLDINGS CO LTD (ACUC)

Phase 4(2)

Drug	Company
Control	Crinetics Pharmaceuticals, Inc. (CRNX)
Dextenza 0.4Mg Ophthalmic Insert	OCULAR THERAPEUTIX, INC (OCUL)

BioSniper tracks 13 drugs in development for Cataract across 9 companies.

There are 7 clinical trials targeting Cataract tracked by BioSniper.

The estimated prevalence of Cataract is approximately 1359.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.